Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNG treatment protocol
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The CNG-Sun Yat-sen University-nasopharyngeal carcinoma protocol (CNG protocol) is a risk-stratified therapeutic strategy for nasopharyngeal carcinoma (NPC) developed by the Cooperative Nasopharyngeal Carcinoma Group at Sun Yat-sen University. This protocol utilizes a proprietary staging system (CNG stage) to guide the administration of Intensity-Modulated Radiation Therapy (IMRT) and a specific chemotherapy regimen. The chemotherapy component includes the intravenous administration of 5-fluorouracil and nedaplatin (or cisplatin), followed by oral adjuvant therapy with tegafur and calcium folinate. The treatment is tailored based on the patient's risk profile and early response to radiation, aiming to optimize tumor control while minimizing long-term toxicities associated with standard chemoradiotherapy guidelines.
- Other names
- CNG-Sun Yat-sen University-nasopharyngeal carcinomaCNG protocolCooperative Nasopharyngeal Carcinoma Group protocol
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on CNG treatment protocol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNG treatment protocol.